Author(s): Hamadani M, Awan FT, Copelan EA
Abstract Share this page
Abstract Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment of many patients with acute myeloid leukemia (AML). Despite extensive study, the appropriate role and timing of allogeneic and autologous transplantation in AML are poorly defined. This review critically analyzes the extensive literature, focusing on the recent advances, and provides practical recommendations for the use of HSCT in AML.
This article was published in Biol Blood Marrow Transplant
and referenced in International Journal of Physical Medicine & Rehabilitation